tiprankstipranks
Advertisement
Advertisement

HK:1541 Stock Latest News

ImmuneOnco Doses First Patient in Phase III Trial of CD47/CD20 Bispecific for Lymphoma
Company AnnouncementsImmuneOnco Doses First Patient in Phase III Trial of CD47/CD20 Bispecific for Lymphoma
9d ago
1541
ImmuneOnco Advances Timdarpacept to Phase III After Strong Leukemia Trial Data
PremiumCompany Announcements
ImmuneOnco Advances Timdarpacept to Phase III After Strong Leukemia Trial Data
14d ago
1541
ImmuneOnco Completes Key Patient Enrollment in Phase III Trial of Lead Cancer Drug IMM01
PremiumCompany Announcements
ImmuneOnco Completes Key Patient Enrollment in Phase III Trial of Lead Cancer Drug IMM01
16d ago
1541
ImmuneOnco Sets March 2026 Board Meeting to Approve 2025 Annual Results
PremiumCompany Announcements
ImmuneOnco Sets March 2026 Board Meeting to Approve 2025 Annual Results
26d ago
1541
ImmuneOnco Wins NMPA IND Nod for New Lupus Candidate Amid Share Price Swings
PremiumCompany Announcements
ImmuneOnco Wins NMPA IND Nod for New Lupus Candidate Amid Share Price Swings
1M ago
1541
ImmuneOnco Grants Connected Loan to Chairman for Tax Compliance Needs
PremiumCompany AnnouncementsImmuneOnco Grants Connected Loan to Chairman for Tax Compliance Needs
2M ago
1541
ImmuneOnco Nears Interim Milestone in Phase III Trial of Lead CD47 Drug IMM01
Premium
Company Announcements
ImmuneOnco Nears Interim Milestone in Phase III Trial of Lead CD47 Drug IMM01
3M ago
1541
ImmuneOnco Wins NMPA Nod to Test Lead CD47 Drug IMM01 in Atherosclerosis
Premium
Company Announcements
ImmuneOnco Wins NMPA Nod to Test Lead CD47 Drug IMM01 in Atherosclerosis
3M ago
1541
ImmuneOnco Reclaims Global Rights to Key Immuno-Oncology Assets IMM2510 and IMM27M
PremiumCompany Announcements
ImmuneOnco Reclaims Global Rights to Key Immuno-Oncology Assets IMM2510 and IMM27M
3M ago
1541
ImmuneOnco CEO Increases Stake, Signaling Confidence in Growth
PremiumCompany Announcements
ImmuneOnco CEO Increases Stake, Signaling Confidence in Growth
4M ago
1541
ImmuneOnco’s Phase III Study of Innovative Lymphoma Treatment Approved
PremiumCompany Announcements
ImmuneOnco’s Phase III Study of Innovative Lymphoma Treatment Approved
4M ago
1541
ImmuneOnco Redeems and Subscribes to Wealth Management Products
PremiumCompany Announcements
ImmuneOnco Redeems and Subscribes to Wealth Management Products
5M ago
1541
ImmuneOnco Biopharmaceuticals Updates Articles Following Share Placement
PremiumCompany AnnouncementsImmuneOnco Biopharmaceuticals Updates Articles Following Share Placement
5M ago
1541
ImmuneOnco CEO Increases Shareholding, Signaling Confidence in Growth
Premium
Company Announcements
ImmuneOnco CEO Increases Shareholding, Signaling Confidence in Growth
5M ago
1541
ImmuneOnco Advances in Cancer Immunotherapy with New Clinical Trial Milestone
Premium
Company Announcements
ImmuneOnco Advances in Cancer Immunotherapy with New Clinical Trial Milestone
6M ago
1541
ImmuneOnco Completes HK$345.1 Million H Share Placement
PremiumCompany Announcements
ImmuneOnco Completes HK$345.1 Million H Share Placement
6M ago
1541
ImmuneOnco Announces HK$350.9 Million H Share Placement
PremiumCompany Announcements
ImmuneOnco Announces HK$350.9 Million H Share Placement
6M ago
1541
ImmuneOnco Advances Lung Cancer Treatment with Phase III Trial Application
PremiumCompany Announcements
ImmuneOnco Advances Lung Cancer Treatment with Phase III Trial Application
6M ago
1541
ImmuneOnco Advances Phase III Trial for Innovative Cancer Therapy
PremiumCompany Announcements
ImmuneOnco Advances Phase III Trial for Innovative Cancer Therapy
6M ago
1541
ImmuneOnco Biopharmaceuticals Reports Promising Interim Results for Oncology Pipeline
PremiumCompany AnnouncementsImmuneOnco Biopharmaceuticals Reports Promising Interim Results for Oncology Pipeline
7M ago
1541
ImmuneOnco Biopharmaceuticals Begins Phase I Trial for IMC-003/IMM72
Premium
Company Announcements
ImmuneOnco Biopharmaceuticals Begins Phase I Trial for IMC-003/IMM72
8M ago
1541
ImmuneOnco Biopharmaceuticals Schedules Board Meeting for Interim Results
Premium
Company Announcements
ImmuneOnco Biopharmaceuticals Schedules Board Meeting for Interim Results
8M ago
1541

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >